Guardian Pharmacy Services (NYSE:GRDN) Insider David Morris Sells 187,855 Shares of Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) insider David Morris sold 187,855 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $5,575,536.40. Following the completion of the transaction, the insider directly owned 254,472 shares in the company, valued at $7,552,728.96. This trade represents a 42.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Guardian Pharmacy Services Stock Down 2.8%

GRDN stock opened at $36.52 on Thursday. The business’s 50-day moving average price is $32.62 and its 200-day moving average price is $29.87. The stock has a market cap of $2.31 billion, a P/E ratio of 47.43 and a beta of 0.86. Guardian Pharmacy Services, Inc. has a twelve month low of $19.17 and a twelve month high of $38.12.

Guardian Pharmacy Services (NYSE:GRDN) last released its earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.10. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The company had revenue of $397.62 million during the quarter, compared to analyst estimates of $390.04 million. The firm’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, equities research analysts expect that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Key Guardian Pharmacy Services News

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Neutral Sentiment: Market writeup noting broad insider activity at Guardian Pharmacy Services; useful context but not new filings. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at an average $29.68 (≈$106.0M). Filing: SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at $29.68 (≈$106.0M). Filing: SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at $29.68 (≈$32.7M). Filing: SEC filing
• Negative Sentiment: Director/officer Fred Burke sold 671,432 shares at $29.68 (≈$19.9M). Filing: SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at $29.68 (≈$10.3M). Filing: SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at $29.68 (≈$5.6M). Filing: SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. Cardinal sold 275,728 shares at $29.68 (≈$8.2M), a ~44% reduction in its stake. Filing: SEC filing

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research report on Monday, December 29th. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 18th. Stephens increased their price target on Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 14th. Truist Financial raised their price target on Guardian Pharmacy Services from $34.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Finally, UBS Group restated a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $38.00.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of institutional investors have recently added to or reduced their stakes in the stock. Boston Partners raised its position in shares of Guardian Pharmacy Services by 418.7% during the third quarter. Boston Partners now owns 1,046,877 shares of the company’s stock valued at $26,922,000 after buying an additional 845,048 shares during the last quarter. Loomis Sayles & Co. L P bought a new position in shares of Guardian Pharmacy Services during the fourth quarter worth $19,126,000. Millennium Management LLC grew its stake in Guardian Pharmacy Services by 725.2% during the third quarter. Millennium Management LLC now owns 342,038 shares of the company’s stock valued at $8,972,000 after acquiring an additional 300,587 shares in the last quarter. Aristotle Capital Boston LLC grew its stake in Guardian Pharmacy Services by 58.5% during the third quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock valued at $17,035,000 after acquiring an additional 239,790 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Guardian Pharmacy Services by 32.2% in the 2nd quarter. Franklin Resources Inc. now owns 976,207 shares of the company’s stock valued at $20,803,000 after acquiring an additional 237,630 shares during the last quarter.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.